KDM2B knockdown reduced cytotoxicity, inflammation and oxidative stress in LPS‐induced AKI via inhibiting NF‐κB and AP‐1 pathways, indicating KDM2B may be a promising therapeutic target for the treatment of sepsis‐associated AKI. This evidence concerns the gene JUN and Sepsis.